The maker of the fat-jab Wegovy hailed surging demand for its first weight-loss pill, after smashing sales forecasts.
Novo Nordisk launched its Wegovy pill in January as it fought back against Eli Lilly, the maker of rival drug Mounjaro, after seeing sales and profits tumble in the face of stiff competition.
The Danish pharmaceutical firm said yesterday that more than 2m prescriptions of the pill had been issued since its launch, with weekly prescriptions exceeding 200,000.
The firm said the Wegovy pill’s launch was the strongest of any obesity drug in the US. Sales of the pill reached £260million in the quarter to March 31, surpassing analyst predictions.
Overall revenue was also ahead of expectations at £8bn.
Miracle pill: Novo Nordisk launched its Wegovy pill in January as it fought back against Eli Lilly, the maker of rival drug Mounjaro, after seeing sales and profits tumble
DIY INVESTING PLATFORMS
Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.